BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2022 11:52:44 AM | Browse: 215 | Download: 827
 |
Received |
|
2022-05-14 12:41 |
|
Peer-Review Started |
|
2022-05-06 08:27 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-06-12 04:55 |
|
Revised |
|
2022-06-26 08:52 |
|
Second Decision |
|
2022-08-19 03:10 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-08-21 17:55 |
|
Articles in Press |
|
2022-08-21 17:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-09-02 06:29 |
|
Publish the Manuscript Online |
|
2022-09-16 11:52 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun-Xia Cao, Jia You, Li-Hua Wu, Kai Luo and Zheng-Xu Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Scientific Research Projects in China |
CLB19J053 |
| Scientific Research Projects in China |
19SWAQ13 |
|
| Corresponding Author |
Zheng-Xu Wang, MD, PhD, Professor, Biotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, No. 5 Nanmencang Road, Dongcheng District, Beijing 100700, China. zhxuwang@qq.com |
| Key Words |
Stem cell; Meta-analysis; COVID-19; Mesenchymal stem cells |
| Core Tip |
In this study, we investigated whether mesenchymal stem cell (MSC) have therapeutic efficacy in novel coronavirus disease 2019 (COVID-19) patients. The analysis showed no significant decrease in C-reactive protein (CRP) levels and a reduction of D-dimer levels was also not observed in patients after stem cell administration. Interleukin 6 (IL-6) demonstrated no decrease after stem cell therapy. There was a significant improvement in overall survival (OS) after stem cell therapy. Overall, our analysis suggests that while MSC therapy for COVID-19 patients does not significantly decrease inflammatory markers such as CRP, D-dimer and IL-6, OS is improved. |
| Publish Date |
2022-09-16 11:52 |
| Citation |
Cao JX, You J, Wu LH, Luo K, Wang ZX. Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review. World J Clin Cases 2022; 10(27): 9714-9726 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i27/9714.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i27.9714 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
